$PPDI Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PHARMACEUTICAL PRODUCT DEVELOPMENT INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PHARMACEUTICAL PRODUCT DEVELOPMENT INC. Get notifications about new insider transactions in PHARMACEUTICAL PRODUCT DEVELOPMENT INC for free.
Page: < prev 1 2 3 4 5 6 7 8 ... 17 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 44.00 | 42,519 | 1,870,836 | 2,950,600 | 3 M to 3 M (-1.42 %) |
May 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 44.00 | 216 | 9,504 | 2,993,119 | 3 M to 3 M (-0.01 %) |
May 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 44.10 | 1,342 | 59,182 | 2,993,335 | 3 M to 3 M (-0.04 %) |
May 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 44.07 | 100 | 4,407 | 2,994,677 | 3 M to 3 M (0.00 %) |
May 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 44.06 | 11,500 | 506,690 | 2,994,777 | 3 M to 3 M (-0.38 %) |
May 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 44.03 | 200 | 8,806 | 3,006,277 | 3 M to 3 M (-0.01 %) |
May 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 44.01 | 400 | 17,604 | 3,006,477 | 3 M to 3 M (-0.01 %) |
May 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 44.00 | 16,694 | 734,536 | 3,006,877 | 3 M to 3 M (-0.55 %) |
May 22 2008 | PPDI | PHARMACEUTICAL PRO ... | GRANGE DAVID L | Director | Option Exercise | A | 42.77 | 6,265 | 267,954 | 6,265 | |
May 22 2008 | PPDI | PHARMACEUTICAL PRO ... | KLEMA CATHY | Director | Option Exercise | A | 42.77 | 6,265 | 267,954 | 6,265 | |
May 22 2008 | PPDI | PHARMACEUTICAL PRO ... | MAGNUSON TERRY | Director | Option Exercise | A | 42.77 | 6,265 | 267,954 | 6,265 | |
May 22 2008 | PPDI | PHARMACEUTICAL PRO ... | FRANK FRED | Director | Option Exercise | A | 42.77 | 6,265 | 267,954 | 6,265 | |
May 22 2008 | PPDI | PHARMACEUTICAL PRO ... | MARIO ERNEST | Director | Option Exercise | A | 42.77 | 6,265 | 267,954 | 6,265 | |
May 22 2008 | PPDI | PHARMACEUTICAL PRO ... | BONDURANT STUART | Director | Option Exercise | A | 42.77 | 6,265 | 267,954 | 6,265 | |
May 22 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Option Exercise | A | 42.77 | 6,265 | 267,954 | 6,265 | |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.60 | 25 | 1,090 | 8,004,626 | 8 M to 8 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.58 | 600 | 26,148 | 8,004,651 | 8 M to 8 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.57 | 1,875 | 81,694 | 8,005,251 | 8 M to 8 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.56 | 1,500 | 65,340 | 8,007,126 | 8 M to 8 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.55 | 7,000 | 304,850 | 8,008,626 | 8 M to 8 M (-0.09 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.54 | 600 | 26,124 | 8,015,626 | 8 M to 8 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.53 | 2,400 | 104,472 | 8,016,226 | 8 M to 8 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.80 | 1,498 | 64,114 | 8,018,626 | 8 M to 8 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.79 | 2,406 | 102,953 | 8,020,124 | 8 M to 8 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.78 | 1,000 | 42,780 | 8,022,530 | 8 M to 8 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.77 | 1,900 | 81,263 | 8,023,530 | 8 M to 8 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.76 | 6,475 | 276,871 | 8,025,430 | 8 M to 8 M (-0.08 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.75 | 7,202 | 307,886 | 8,031,905 | 8 M to 8 M (-0.09 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.74 | 3,000 | 128,220 | 8,039,107 | 8 M to 8 M (-0.04 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.73 | 5,525 | 236,083 | 8,042,107 | 8 M to 8 M (-0.07 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.72 | 2,324 | 99,281 | 8,047,632 | 8 M to 8 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.71 | 9,200 | 392,932 | 8,049,956 | 8.1 M to 8 M (-0.11 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.70 | 8,620 | 368,074 | 8,059,156 | 8.1 M to 8.1 M (-0.11 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.69 | 1,000 | 42,690 | 8,067,776 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.68 | 1,200 | 51,216 | 8,068,776 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.66 | 1,600 | 68,256 | 8,069,976 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.65 | 5,900 | 251,635 | 8,071,576 | 8.1 M to 8.1 M (-0.07 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.64 | 2,270 | 96,793 | 8,077,476 | 8.1 M to 8.1 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.63 | 4,100 | 174,783 | 8,079,746 | 8.1 M to 8.1 M (-0.05 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.62 | 5,900 | 251,458 | 8,083,846 | 8.1 M to 8.1 M (-0.07 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.61 | 638 | 27,185 | 8,089,746 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.60 | 2,042 | 86,989 | 8,090,384 | 8.1 M to 8.1 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.59 | 3,400 | 144,806 | 8,092,426 | 8.1 M to 8.1 M (-0.04 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.57 | 1,400 | 59,598 | 8,095,826 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.55 | 5,700 | 242,535 | 8,095,286 | 8.1 M to 8.1 M (-0.07 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.53 | 3,600 | 153,108 | 8,102,926 | 8.1 M to 8.1 M (-0.04 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.52 | 8,100 | 344,412 | 8,106,526 | 8.1 M to 8.1 M (-0.10 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.83 | 122 | 5,225 | 8,114,626 | 8.1 M to 8.1 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.84 | 300 | 12,852 | 8,114,748 | 8.1 M to 8.1 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.86 | 778 | 33,345 | 8,115,048 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.91 | 1,100 | 47,201 | 8,115,826 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.87 | 445 | 19,077 | 8,116,926 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.90 | 5,000 | 214,500 | 8,117,371 | 8.1 M to 8.1 M (-0.06 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.92 | 2,055 | 88,201 | 8,122,371 | 8.1 M to 8.1 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 42.93 | 1,900 | 81,567 | 8,124,426 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.02 | 1,012 | 43,536 | 8,126,326 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.00 | 5,098 | 219,214 | 8,127,338 | 8.1 M to 8.1 M (-0.06 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.01 | 1,900 | 81,719 | 8,132,436 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.06 | 2,762 | 118,932 | 8,134,336 | 8.1 M to 8.1 M (-0.03 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.08 | 800 | 34,464 | 8,137,098 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.09 | 290 | 12,496 | 8,137,898 | 8.1 M to 8.1 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.07 | 1,438 | 61,935 | 8,138,188 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.05 | 1,000 | 43,050 | 8,139,626 | 8.1 M to 8.1 M (-0.01 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.02 | 396 | 17,036 | 8,140,626 | 8.1 M to 8.1 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.03 | 100 | 4,303 | 8,141,022 | 8.1 M to 8.1 M (0.00 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.11 | 2,000 | 86,220 | 8,141,122 | 8.1 M to 8.1 M (-0.02 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.12 | 3,804 | 164,028 | 8,143,122 | 8.1 M to 8.1 M (-0.05 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.10 | 5,503 | 237,179 | 8,146,926 | 8.2 M to 8.1 M (-0.07 %) |
May 21 2008 | PPDI | PHARMACEUTICAL PRO ... | ESHELMAN FREDRIC N | CEO | Sell | S | 43.11 | 2,197 | 94,713 | 8,152,429 | 8.2 M to 8.2 M (-0.03 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Option Exercise | M | 15.30 | 20,000 | 306,000 | 0 | |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.86 | 98 | 4,200 | 0 | 98 to 0 (-100.00 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.85 | 300 | 12,855 | 98 | 398 to 98 (-75.38 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.84 | 2 | 86 | 398 | 400 to 398 (-0.50 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.82 | 384 | 16,443 | 400 | 784 to 400 (-48.98 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.81 | 500 | 21,405 | 784 | 1.3 K to 784 (-38.94 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.79 | 402 | 17,202 | 1,284 | 1.7 K to 1.3 K (-23.84 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.71 | 1,588 | 67,823 | 1,686 | 3.3 K to 1.7 K (-48.50 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.70 | 1,100 | 46,970 | 3,274 | 4.4 K to 3.3 K (-25.15 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.69 | 300 | 12,807 | 4,374 | 4.7 K to 4.4 K (-6.42 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.68 | 900 | 38,412 | 4,674 | 5.6 K to 4.7 K (-16.15 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.67 | 900 | 38,403 | 5,574 | 6.5 K to 5.6 K (-13.90 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.66 | 200 | 8,532 | 6,474 | 6.7 K to 6.5 K (-3.00 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.65 | 1,232 | 52,545 | 6,674 | 7.9 K to 6.7 K (-15.58 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.64 | 1,200 | 51,168 | 7,906 | 9.1 K to 7.9 K (-13.18 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.63 | 400 | 17,052 | 9,106 | 9.5 K to 9.1 K (-4.21 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.59 | 100 | 4,259 | 9,506 | 9.6 K to 9.5 K (-1.04 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.55 | 100 | 4,255 | 9,606 | 9.7 K to 9.6 K (-1.03 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.54 | 600 | 25,524 | 9,706 | 10.3 K to 9.7 K (-5.82 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.53 | 1,800 | 76,554 | 10,306 | 12.1 K to 10.3 K (-14.87 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.52 | 1,299 | 55,233 | 12,106 | 13.4 K to 12.1 K (-9.69 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 41.51 | 6,195 | 257,154 | 13,405 | 19.6 K to 13.4 K (-31.61 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Sell | S | 42.50 | 400 | 17,000 | 19,600 | 20 K to 19.6 K (-2.00 %) |
May 06 2008 | PPDI | PHARMACEUTICAL PRO ... | HARTMAN JUDD | General Counsel | Buy | M | 15.30 | 20,000 | 306,000 | 20,000 | 0 to 20 K |
Mar 14 2008 | PPDI | PHARMACEUTICAL PRO ... | MARIO ERNEST | Director | Option Exercise | M | 6.25 | 16,000 | 100,000 | 0 | |
Mar 14 2008 | PPDI | PHARMACEUTICAL PRO ... | MARIO ERNEST | Director | Buy | M | 6.25 | 16,000 | 100,000 | 452,257 | 436.3 K to 452.3 K (+3.67 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 47.09 | 200 | 9,418 | 262 | 462 to 262 (-43.29 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 47.08 | 1,300 | 61,204 | 462 | 1.8 K to 462 (-73.78 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 47.07 | 400 | 18,828 | 1,762 | 2.2 K to 1.8 K (-18.50 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 47.05 | 2,200 | 103,510 | 2,162 | 4.4 K to 2.2 K (-50.44 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.96 | 100 | 4,696 | 4,362 | 4.5 K to 4.4 K (-2.24 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.91 | 200 | 9,382 | 4,462 | 4.7 K to 4.5 K (-4.29 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.90 | 4,200 | 196,980 | 4,662 | 8.9 K to 4.7 K (-47.39 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.85 | 200 | 9,370 | 8,862 | 9.1 K to 8.9 K (-2.21 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.84 | 100 | 4,684 | 9,062 | 9.2 K to 9.1 K (-1.09 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.82 | 100 | 4,682 | 9,162 | 9.3 K to 9.2 K (-1.08 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.78 | 400 | 18,712 | 9,262 | 9.7 K to 9.3 K (-4.14 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.77 | 500 | 23,385 | 9,662 | 10.2 K to 9.7 K (-4.92 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.75 | 100 | 4,675 | 10,162 | 10.3 K to 10.2 K (-0.97 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 47.05 | 196 | 9,222 | 10,262 | 10.5 K to 10.3 K (-1.87 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Option Exercise | M | 34.62 | 26,666 | 923,177 | 13,334 | |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Option Exercise | M | 33.61 | 10,000 | 336,100 | 20,000 | |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 47.05 | 100 | 4,705 | 11,058 | 11.2 K to 11.1 K (-0.90 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 47.00 | 100 | 4,700 | 11,158 | 11.3 K to 11.2 K (-0.89 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.98 | 1,666 | 78,269 | 11,258 | 12.9 K to 11.3 K (-12.89 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.97 | 369 | 17,332 | 12,924 | 13.3 K to 12.9 K (-2.78 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.95 | 645 | 30,283 | 13,293 | 13.9 K to 13.3 K (-4.63 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.94 | 300 | 14,082 | 13,938 | 14.2 K to 13.9 K (-2.11 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.93 | 900 | 42,237 | 13,638 | 14.5 K to 13.6 K (-6.19 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.92 | 888 | 41,665 | 14,538 | 15.4 K to 14.5 K (-5.76 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.91 | 631 | 29,600 | 15,426 | 16.1 K to 15.4 K (-3.93 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.90 | 3,955 | 185,490 | 16,057 | 20 K to 16.1 K (-19.76 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.89 | 1,300 | 60,957 | 20,012 | 21.3 K to 20 K (-6.10 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.88 | 2,300 | 107,824 | 21,312 | 23.6 K to 21.3 K (-9.74 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.87 | 1,600 | 74,992 | 23,612 | 25.2 K to 23.6 K (-6.35 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.86 | 1,000 | 46,860 | 25,212 | 26.2 K to 25.2 K (-3.82 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.85 | 1,800 | 84,330 | 26,212 | 28 K to 26.2 K (-6.43 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.84 | 1,100 | 51,524 | 28,012 | 29.1 K to 28 K (-3.78 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.82 | 200 | 9,364 | 29,112 | 29.3 K to 29.1 K (-0.68 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.81 | 100 | 4,681 | 29,312 | 29.4 K to 29.3 K (-0.34 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.80 | 700 | 32,760 | 29,412 | 30.1 K to 29.4 K (-2.32 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.79 | 36 | 1,684 | 30,112 | 30.1 K to 30.1 K (-0.12 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.78 | 64 | 2,994 | 30,148 | 30.2 K to 30.1 K (-0.21 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.73 | 100 | 4,673 | 30,212 | 30.3 K to 30.2 K (-0.33 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.71 | 200 | 9,342 | 30,312 | 30.5 K to 30.3 K (-0.66 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.69 | 500 | 23,345 | 30,512 | 31 K to 30.5 K (-1.61 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.68 | 800 | 37,344 | 31,012 | 31.8 K to 31 K (-2.51 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.67 | 3,216 | 150,091 | 31,812 | 35 K to 31.8 K (-9.18 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.64 | 100 | 4,664 | 35,028 | 35.1 K to 35 K (-0.28 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.60 | 1,800 | 83,880 | 35,128 | 36.9 K to 35.1 K (-4.87 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Buy | M | 33.61 | 10,000 | 336,100 | 36,928 | 26.9 K to 36.9 K (+37.14 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Buy | M | 34.61 | 26,666 | 922,910 | 26,928 | 262 to 26.9 K (+10,177.86 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Option Exercise | M | 5.97 | 16,000 | 95,520 | 0 | |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 47.00 | 5,404 | 253,988 | 3,023,571 | 3 M to 3 M (-0.18 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 47.10 | 900 | 42,390 | 3,028,975 | 3 M to 3 M (-0.03 %) |
Feb 29 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Buy | M | 5.97 | 16,000 | 95,520 | 41,471 | 25.5 K to 41.5 K (+62.82 %) |
Feb 27 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 47.20 | 596 | 28,131 | 3,029,875 | 3 M to 3 M (-0.02 %) |
Feb 27 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 47.15 | 5,000 | 235,750 | 3,030,471 | 3 M to 3 M (-0.16 %) |
Feb 27 2008 | PPDI | PHARMACEUTICAL PRO ... | MCNEILL JOHN A JR | Director | Sell | S | 46.90 | 9,950 | 466,655 | 3,035,471 | 3 M to 3 M (-0.33 %) |
Feb 28 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Option Exercise | M | 21.19 | 25,000 | 529,750 | 25,000 | |
Feb 28 2008 | PPDI | PHARMACEUTICAL PRO ... | COVINGTON PAUL S | Executive Vice Pres ... | Sell | S | 46.75 | 1,962 | 91,724 | 262 | 2.2 K to 262 (-88.22 %) |